CSL (ASX:CSL) said it is continuing to assess the broader impact of the newly imposed US tariffs and will monitor further announcements by the US Government, according to a Thursday Australian bourse filing.
The company noted that, currently, pharmaceutical products are not subject to the reciprocal tariffs.
The company intends to work with the US administration to ensure American patients retain access to its medicines, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.